# Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

> **NCT00300963** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 275 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Talnetant

## Key facts

- **NCT ID:** NCT00300963
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 275 (—)
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300963, "Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00300963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*